Akademik Veri Yönetim Sistemi
5th Congress of the European Academy of Pediatric Societies, Barcelona, İspanya, 17 - 21 Ekim 2014, cilt.99, ss.508, (Özet Bildiri)
feine seems to be effective for reducing the risk of bronchopulmonary dysplasia and for decreasing the need for reintubation.
We aimed to evaluate the effects of caffeine therapy on respiratory morbidities in very low birth weights infants.
Method We aimed to review patient records for a 5 year period
(2008–2013) retrospectively. Infants whose birth weight <1250
gr and gestational age <32 weeks were studied. Data collected
for analysis included patient demographics, respiratory morbidities and mortality.
Results A total of 290 patient records were analysed, of them
148 infants were treated with caffeine (CT+),142 infant did not
receive caffeine therapy (CT-). Gestational ages (27.9 ± 2 vs
27.7 ± 2.7 weeks) and birth weights (967 ± 186 vs 980 ± 196
g) were similar between groups (p > 0.05). Basic characteristics
and risk factors were similar between groups. CPAP failure was
significantly lower in CT+ group (25,4% vs 41.1%, p = 0.02)
Oxygen requirement on 36 weeks (13.2% vs 7.4% in CT+ and
CT- groups respectively) were similar between groups (p > 0.05).
Mortality rate (18.9% vs 54%), BPD or death (28.6% vs 57%)
and duration of mechanical ventilation (2.9 ± 5 vs 4.8 ± 7.7
days) were significantly lower in CT+ group (p < 0.01).
Conclusion We demonstrated that caffeine therapy significantly
reduced the mortality rate, death or BPD and CPAP failure
VLBW infant yet no significant difference was observed on therates of BPD. This is an ongoing study and maybe the final analysis will yield different results.